BNC Korea Co., Ltd. (KOSDAQ:256840)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,520.00
-85.00 (-1.85%)
At close: Feb 27, 2026
2.03%
Market Cap 309.14B
Revenue (ttm) 98.11B
Net Income (ttm) 13.76B
Shares Out 68.39M
EPS (ttm) 201.77
PE Ratio 22.38
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 744,575
Average Volume 1,630,294
Open 4,600.00
Previous Close 4,605.00
Day's Range 4,500.00 - 4,635.00
52-Week Range 3,475.00 - 6,310.00
Beta 0.66
RSI 38.59
Earnings Date Mar 20, 2026

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers ... [Read more]

Sector Healthcare
Founded 2007
Employees 250
Stock Exchange KOSDAQ
Ticker Symbol 256840
Full Company Profile

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.

Financial Statements

News

There is no news available yet.